| 1. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1):5-29.
|
| 2. |
Thota R, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma:a review[J]. Oncology (Williston Park), 2014, 28(1):70-74.
|
| 3. |
李兆申. 胰腺癌早期诊断研究现状及展望[J]. 临床肝胆病杂志, 2010, 26(5):451-453.
|
| 4. |
楼文辉. 局部晚期和转移性胰腺癌的综合治疗[J]. 上海医学, 2010, 33(11):992-994.
|
| 5. |
Vaccaro V, Sperduti I, Milella M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 365(8):768-769.
|
| 6. |
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364(19):1817-1825.
|
| 7. |
Zagouri F, Sergentanis TN, Chrysikos D, et al. Molecularly targeted therapies in metastatic pancreatic cancer:a systematic review[J]. Pancreas, 2013, 42(5):760-773.
|
| 8. |
Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection:a randomized controlled trial[J]. JAMA, 2010, 304(10):1073-1081.
|
| 9. |
Hartwig W, Werner J, Jäger D, et al. Improvement of surgical results for pancreatic cancer[J]. Lancet Oncol, 2013, 14(11):e476-e485.
|
| 10. |
Greenhalf W, Ghaneh P, Neoptolemos JP, et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial[J]. J Natl Cancer Inst, 2014, 106(1):djt347.
|
| 11. |
Neoptolemos JP, Stocken DD, Tudur Smith C, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer:composite data from the ESPAC-1and -3(v1) trials[J]. Br J Cancer, 2009, 100(2):246-250.
|
| 12. |
Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer:the CONKO-001 randomized trial[J]. JAMA, 2013, 310(14):1473-1481.
|
| 13. |
Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase Ⅲ trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer:Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer[J]. Br J Cancer, 2009, 101(6):908-915.
|
| 14. |
Maeda A, Boku N, Fukutomi A, et al. Randomized phase Ⅲ trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer:Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)[J]. Jpn J Clin Oncol, 2008, 38(3):227-229.
|
| 15. |
Fukutomi A, Uesaka K, Boku N, et al. JASPAC 01:randomized phase Ⅲ trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer[C/OL]. 2013 ASCO Annual Meeting. http://meetinglibrary.asco.org/content/116237-132.
|
| 16. |
Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J]. J Clin Oncol, 1997, 15(6):2403-2413.
|
| 17. |
Poplin E, Feng Y, Berlin J, et al. Phase Ⅲ, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201:a trial of the Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2009, 27(23):3778-3785.
|
| 18. |
Cunningham D, Chau I, Stocken DD, et al. Phase Ⅲ randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer[J]. J Clin Oncol, 2009, 27(33):5513-5518.
|
| 19. |
Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase Ⅲ trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer[J]. J Clin Oncol, 2006, 24(24):3946-3952.
|
| 20. |
Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase Ⅲ trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer:the GIP-1 study[J]. J Clin Oncol, 2010, 28(10):1645-1651.
|
| 21. |
Kindler HL, Friberg G, Singh DA, et al. Phase Ⅱ trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer[J]. J Clin Oncol, 2005, 23(31):8033-8040.
|
| 22. |
Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer:phase Ⅲ trial of the Cancer and Leukemia Group B (CALGB 80303)[J]. J Clin Oncol, 2010, 28(22):3617-3622.
|
| 23. |
Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase Ⅲ trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer[J]. Br J Cancer, 2006, 95(5):587-592.
|
| 24. |
Oettle H, Richards D, Ramanathan RK, et al. A phase Ⅲ trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer[J]. Ann Oncol, 2005, 16(10):1639-1645.
|
| 25. |
Philip PA, Benedetti J, Corless CL, et al. Phase Ⅲ study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma:Southwest Oncology Group-directed intergroup trial S0205[J]. J Clin Oncol, 2010, 28(22):3605-3610.
|
| 26. |
Kasuga A, Okano N, Naruge D, et al. Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer:inflammation-based prognostic score predicts survival[J]. Cancer Chemother Pharmacol, 2015, 75(3):457-464.
|
| 27. |
Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer——a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study[J]. J Clin Oncol, 2005, 23(6):1228-1236.
|
| 28. |
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369(18):1691-1703.
|
| 29. |
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25(15):1960-1966.
|
| 30. |
Yang ZY, Yuan JQ, Di MY, et al. Gemcitabine plus erlotinib for advanced pancreatic cancer:a systematic review with meta-analysis[J]. PLoS One, 2013, 8(3):e57528.
|
| 31. |
Epstein AS, Abou-Alfa GK, Shamseddine A, et al. Communication and palliative care in a 64-year-old man with pancreatic adenocarcinoma[J]. Gastrointest Cancer Res, 2012, 5(4):130-134.
|
| 32. |
Middleton GW, Valle JW, Wadsley J, et al. A phase Ⅲ randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer[J]. J Clin Oncol, 2013, 31(18 Suppl):LBA4004.
|
| 33. |
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer[J]. N Engl J Med, 2010, 363(8):733-742.
|
| 34. |
MA Rodriguez, YA Dejesus, L Cheng, et al. Factors related to end-of-life (EOL) chemotherapy in solid tumor (ST) patients[J]. J Clin Oncol, 2013, 31(31):334-350.
|
| 35. |
Romanus D, Kindler HL, Archer L, et al. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase Ⅲ trial of the cancer and leukemia group B (CALGB 80303)[J]. J Pain Symptom Manage, 2012, 43(2):205-217.
|
| 36. |
Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer[J]. JAMA, 2009, 301(24):2553-2562.
|
| 37. |
Greer JA, Pirl WF, Jackson VA, et al. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer[J]. J Clin Oncol, 2012, 30(4):394-400.
|
